BACKGROUND AND AIMS: Pancreatic cancer is among the most dismal of human malignancies. There are no chemopreventive strategies for pancreatic cancer or its precursor lesions, pancreatic intraepithelial neoplasia (PanINs). Recent evidence suggests that statins have potential chemopreventive abilities. In this study, we used a genetically engineered mouse model of pancreatic cancer to evaluate the chemopreventive potential of this drug. METHODS: Simvastatin was injected i.p. in LsL-Kras(G12D); Pdx1-Cre or LsL-Kras(G12D);LsL-Trp53(R172H);Pdx1-Cre mice. After five months, animals were sacrificed. The effect of simvastatin was evaluated by histopathological analyses, immunostaining, and real-time PCR. RESULTS: After five months of treatment, simvastatin was able to significantly delay progression of mPanINs in LsL-Kras(G12D); Pdx1-Cre mice. Furthermore, formation of invasive pancreatic cancer in LsL-Kras(G12D); LsL-Trp53(R172H); Pdx1-Cre transgenic mice was partially inhibited by simvastatin. Invasive murine pancreatic cancer was identified in 9 of 12 (75%) LsL-Kras(G12D); LsL-Trp53(R172H);Pdx1-Cre untreated control mice. In contrast, transgenic mice treated with Simvastatin, only 4 out of 10 (40%, p = 0.004) developed murine pancreatic cancer during the study. Using real-time PCR we found a significant up-regulation of Hmgcr as sign of blocking HMG-CoA reductase, a key enzyme in the cholesterol biosynthesis. This shows our ability to achieve effective pharmacologic levels of simvastatin during pancreatic cancer formation in vivo. CONCLUSION: Using a transgenic mouse model that recapitulates human pancreatic cancer, this study provides first evidence that simvastatin is an effective chemopreventive agent by delaying the progression of PanINs and partially inhibit the formation of murine pancreatic cancer.
BACKGROUND AND AIMS: Pancreatic cancer is among the most dismal of humanmalignancies. There are no chemopreventive strategies for pancreatic cancer or its precursor lesions, pancreatic intraepithelial neoplasia (PanINs). Recent evidence suggests that statins have potential chemopreventive abilities. In this study, we used a genetically engineered mouse model of pancreatic cancer to evaluate the chemopreventive potential of this drug. METHODS:Simvastatin was injected i.p. in LsL-Kras(G12D); Pdx1-Cre or LsL-Kras(G12D);LsL-Trp53(R172H);Pdx1-Cre mice. After five months, animals were sacrificed. The effect of simvastatin was evaluated by histopathological analyses, immunostaining, and real-time PCR. RESULTS: After five months of treatment, simvastatin was able to significantly delay progression of mPanINs in LsL-Kras(G12D); Pdx1-Cre mice. Furthermore, formation of invasive pancreatic cancer in LsL-Kras(G12D); LsL-Trp53(R172H); Pdx1-Cre transgenic mice was partially inhibited by simvastatin. Invasive murinepancreatic cancer was identified in 9 of 12 (75%) LsL-Kras(G12D); LsL-Trp53(R172H);Pdx1-Cre untreated control mice. In contrast, transgenic mice treated with Simvastatin, only 4 out of 10 (40%, p = 0.004) developed murinepancreatic cancer during the study. Using real-time PCR we found a significant up-regulation of Hmgcr as sign of blocking HMG-CoA reductase, a key enzyme in the cholesterol biosynthesis. This shows our ability to achieve effective pharmacologic levels of simvastatin during pancreatic cancer formation in vivo. CONCLUSION: Using a transgenic mouse model that recapitulates humanpancreatic cancer, this study provides first evidence that simvastatin is an effective chemopreventive agent by delaying the progression of PanINs and partially inhibit the formation of murinepancreatic cancer.
Authors: Tsuyoshi Hamada; Natalia Khalaf; Chen Yuan; Ana Babic; Vicente Morales-Oyarvide; Zhi Rong Qian; Jonathan Andrew Nowak; Kimmie Ng; Peter Kraft; Douglas Adam Rubinson; Meir Jonathan Stampfer; Edward Luciano Giovannucci; Charles Stewart Fuchs; Shuji Ogino; Brian Matthew Wolpin Journal: J Gastroenterol Date: 2018-01-23 Impact factor: 7.527
Authors: Michael S Simon; Pinkal Desai; Robert Wallace; Chunyuan Wu; Barbara V Howard; Lisa W Martin; Nicolas Schlecht; Simin Liu; Allison Jay; Erin S LeBlanc; Thomas Rohan; JoAnn Manson Journal: Cancer Causes Control Date: 2016-02-09 Impact factor: 2.506
Authors: Bechien U Wu; Jonathan Chang; Christie Y Jeon; Stephen J Pandol; Brian Huang; Eunis W Ngor; Andrew L Difronzo; Robert M Cooper Journal: Am J Gastroenterol Date: 2015-07-21 Impact factor: 10.864
Authors: Mark Steven Miller; Peter Allen; Teresa A Brentnall; Michael Goggins; Ralph H Hruban; Gloria M Petersen; Chinthalapally V Rao; David C Whitcomb; Randall E Brand; Suresh T Chari; Alison P Klein; David M Lubman; Andrew D Rhim; Diane M Simeone; Brian M Wolpin; Asad Umar; Sudhir Srivastava; Vernon E Steele; Jo Ann S Rinaudo Journal: Pancreas Date: 2016-09 Impact factor: 3.327
Authors: Tsuyoshi Hamada; Natalia Khalaf; Chen Yuan; Vicente Morales-Oyarvide; Ana Babic; Jonathan A Nowak; Zhi Rong Qian; Kimmie Ng; Douglas A Rubinson; Peter Kraft; Edward L Giovannucci; Meir J Stampfer; Charles S Fuchs; Shuji Ogino; Brian M Wolpin Journal: Clin Gastroenterol Hepatol Date: 2018-02-21 Impact factor: 11.382
Authors: Shi-He Liu; Juehua Yu; Justin F Creeden; Jeffrey M Sutton; Stephen Markowiak; Robbi Sanchez; John Nemunaitis; Andrea Kalinoski; Jian-Ting Zhang; Robert Damoiseaux; Paul Erhardt; F Charles Brunicardi Journal: Cancer Lett Date: 2020-08-21 Impact factor: 8.679